Recent Quotes

My Watchlist

Indicators

(CSE: MDMA )

0.2300 +0.0100 (+4.55%)

Official Closing Price Updated: 3:59 PM EST, Nov 8, 2024 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	762,938
Open	0.2400
Bid (Size)	0.2250 (500)
Ask (Size)	0.2300 (98,500)
Prev. Close	0.2200
Today's Range	0.2200 - 0.2400
52wk Range	0.0650 - 0.3500
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

PharmAla to supply Mt. Sinai Hospital with LaNeo MDMA

October 21, 2024

From PharmAla Biotech

Via GlobeNewswire

PharmAla Launches MDMA Clinical Trial Tool for Researchers

August 22, 2024

From PharmAla Biotech

Via GlobeNewswire

Performance

YTD	+53.33%	+53.33%
1 Month	+130.00%	+130.00%
3 Month	+130.00%	+130.00%
6 Month	+21.05%	+21.05%
1 Year	+119.05%	+119.05%

More News

PharmAla Comments on USFDA Decision regarding MDMA-Assisted Therapy and Announces Patent Granting for ALA-002

August 09, 2024

From PharmAla Biotech

Via GlobeNewswire

Canadian Biotech Duo Hits Psilocybin Extraction Milestone For API Development At Scale

May 29, 2024

Via Benzinga

Cortexa Commences Manufacturing GMP LaNeo™ MDMA in Australia

April 05, 2024

From PharmAla Biotech

Via GlobeNewswire

Patent Allowance Granted for ALA-002 Composition by US Patent and Trademark Office

March 27, 2024

From PharmAla Biotech

Via GlobeNewswire

Patent Allowance Granted for P-1 Molecule by US Patent and Trademark Office

March 20, 2024

From PharmAla Biotech

Via GlobeNewswire

Cortexa Leads the World in First Supply of Psilocybin Under the TGA’s Authorized Prescriber Scheme

March 18, 2024

From PharmAla Biotech

Via GlobeNewswire

PharmAla receives new “MDXXF” ticker from FINRA for OTCQB Listing

January 24, 2024

From PharmAla Biotech

Via GlobeNewswire

PharmAla-1 Molecule Receives US Patent Prosecution Highway Acceptance

January 08, 2024

From PharmAla Biotech

Via GlobeNewswire

PharmAla Begins Trading on OTCQB

September 06, 2023

From PharmAla Biotech

Via GlobeNewswire

PharmAla Files Patent for Novel MDXX Molecule PharmAla-1

July 31, 2023

From PharmAla Biotech

Via GlobeNewswire

Life Science Investor Forum: Presentations Now Available for Online Viewing

June 23, 2023

From Virtual Investor Conferences

Via GlobeNewswire

Life Science Investor Forum Agenda Announced for June 22nd

June 20, 2023

From Virtual Investor Conferences

Via GlobeNewswire

USFDA Approves LaNeo MDMA for Clinical Trial Use in the United States

June 09, 2023

From PharmAla Biotech

Via GlobeNewswire

PharmAla Biotech to form Australian Psychedelics Joint Venture with Vitura Health

May 01, 2023

From PharmAla Biotech

Via GlobeNewswire

Revive Therapeutics Secures MDMA Supply from PharmAla Biotech for MDMA Transdermal Patch Development

February 06, 2023

From Revive Therapeutics Ltd.

Via GlobeNewswire

Australia Allows Prescription of MDMA and Psilocybin in Groundbreaking Regulatory Change

February 03, 2023

From PharmAla Biotech

Via GlobeNewswire

The Power Play by The Market Herald Releases New Interviews with Pharmala Biotech Holdings, Nextech AR Solutions and Enertopia Discussing Their Latest News

January 27, 2023

Via ACCESSWIRE

KCSA Mental Health Virtual Investor Conference: Presentations Now Available for Online Viewing

December 16, 2022

From Virtual Investor Conferences

Via GlobeNewswire

PharmAla Completes Pre-IND Meeting with FDA, to Present at KCSA Virtual Investor Conference

December 13, 2022

From Virtual Investor Conferences

Via GlobeNewswire

KCSA Mental Health Virtual Investor Conference Agenda Announced for December 15th

December 13, 2022

From Virtual Investor Conferences

Via GlobeNewswire

Mindset Pharma and PharmAla Biotech Enter into Exclusive Sales Agreement

November 16, 2022

From PharmAla Biotech

Via GlobeNewswire

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.